IP Library › Granted Patent US 10,842,728

Granted Patent B2

US 10,842,728 · App. 15/682,388 · Granted Nov 24, 2020

Light-absorbing compositions and methods of use

Inventor: Jiwu Wang (La Jolla, CA)

Assignee: Allele Biotechnology & Pharmaceuticals, Inc.

A61K8/64 A61K8/987 A61K38/1767 A61Q17/04 C07K14/43504 A61K49/0045 A61K2800/434 C09C2210/50

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 10,842,728
App. No.: 15/682,388
Granted: Nov 24, 2020
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.

Claims (165)

1. A method for protecting the skin from light damage in a subject in need thereof, comprising topically administering a formulation comprising a dermatologically acceptable carrier or a vehicle and a functional Brachiostoma light absorbing protein polypeptide comprising the sequence from the N-terminus:

(SEQ ID NO: 15)

Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-

Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-Xaa18-

Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24-Xaa25-Xaa26-

Xaa27-Xaa28-Xaa29-Xaa30-Xaa31-Xaa32-Xaa33-Xaa34-

Xaa35-Xaa36-Xaa37-Xaa38-Xaa39-Xaa40-Xaa41-Xaa42-

Xaa43-Xaa44-Glu45-Xaa46-Xaa47-Xaa48-Xaa49-Xaa50-

Xaa51-Xaa52-Xaa53-Xaa54-Xaa55-Xaa56-Xaa57-Xaa58-

Xaa59-Xaa60-Trp61-Xaa62-Xaa63-Xaa64-Pro65-Xaa66-

Xaa67-Gly68-Tyr69-Gly70-Phe71-His72-Xaa73-Xaa74-

Xaa75-Xaa76-Xaa77-Xaa78-Xaa79-Xaa80-Xaa81-Xaa82-

Xaa83-Xaa84-Xaa85-Xaa86-Xaa87-Xaa88-Xaa89-Xaa90-

Xaa91-Xaa92-Xaa93-Xaa94-Xaa95-Xaa96-Xaa97-Xaa98-

Xaa99-Xaa100-Xaa101-Xaa102-Xaa103-Xaa104-Xaa105-

Xaa106-Xaa107-Xaa108-Xaa109-Xaa110-Xaa111-Tyr112-

Xaa113-Xaa114-Xaa115-Xaa116-Xaa117-Xaa118-Xaa119-

Xaa120-Xaa121-Xaa122-Xaa123-Xaa124-Xaa125-Xaa126-

Xaa127-Xaa128-Xaa129-Xaa130-Xaa131-Xaa132-Xaa133-

Xaa134-Xaa135-Xaa136-Xaa137-Xaa138-Xaa139-Xaa140-

Xaa141-Xaa142-Xaa143-Xaa144-Xaa145-Xaa146-Xaa147-

Xaa148-Xaa149-Xaa150-Xaa151-Xaa152-Xaa153-Xaa154-

Xaa155-Xaa156-Xaa157-Xaa158-Xaa159-Xaa160-Xaa161-

Xaa162-Xaa163-Xaa164-Xaa165-Xaa166-Trp167-Xaa168-

Tyr169-Xaa170-Xaa171-Xaa172-Xaa173-Xaa174-Xaa175-

Xaa176-Xaa177-Xaa178-Xaa179-Xaa180-Xaa181-Xaa182-

Xaa183-Xaa184-Xaa185-Xaa186-Xaa187-Xaa188-Xaa189-

Xaa190-Xaa191-Xaa192-Xaa193-Xaa194-Xaa195-Xaa196-

Xaa197-Xaa198-Xaa199-Xaa200-Xaa201-Xaa202-Xaa203-

Xaa204-Arg205-Xaa206-Xaa207-Xaa208-Xaa209-Xaa210-

Xaa211-Xaa212-Xaa213-Xaa214-Xaa215-Xaa216-Xaa217-

Xaa218-Xaa219-Glu220-Xaa221-Xaa222-Xaa223-Xaa224-

Xaa225,

wherein the polypeptide sequence has no more than 5 substitutions to that of SEQ ID NO: 11 or SEQ ID NO: 12,

wherein Xaa is any amino acid.

2. A method for protecting the skin from light damage in a subject in need thereof, comprising topically administering a formulation comprising a dermatologically acceptable carrier or a vehicle and a functional Brachiostoma light absorbing protein polypeptide specified by the sequence from the N-terminus:

(SEQ ID NO: 15)

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Glu45 Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp61 Xaa Xaa

Xaa Pro65 Xaa Xaa Gly68 Tyr69 Gly70 Phe71 His72 Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Tyr112 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Trp167 Xaa Tyr169 Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Arg205 Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu220 Xaa Xaa Xaa

Xaa Xaa,

wherein the polypeptide sequence has no more than 5 substitutions to that of SEQ ID NO: 3 or SEQ ID NO: 4,

wherein Xaa is any amino acid.

3. A method for protecting the skin from light damage in a subject in need thereof, comprising topically administering a formulation comprising a dermatologically acceptable carrier or a vehicle and a functional Brachiostoma light absorbing protein polypeptide specified by the sequence from the N-terminus:

(SEQ ID NO: 16)

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Gln45 Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp61 Xaa Xaa

Xaa Pro65 Xaa Xaa Gly68 Tyr69 Gly70 Phe71 Tyr72 Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

His113 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Asp152 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Trp168 Xaa Tyr170 Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Arg206 Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln221 Xaa Xaa

Xaa Xaa,

wherein the polypeptide sequence has no more than 5 substitutions to that of SEQ ID NO: 3 or SEQ ID NO: 4,

wherein Xaa is any amino acid.

4. The method of any one of claim 1 , 2 , or 3 wherein the functional recombinant multimeric Brachiostoma light absorbing protein polypeptides formulated for topical administration comprises polypeptides that are tetramers, trimers or dimers.

5. The method of claim 4 wherein the functional recombinant Brachiostoma light absorbing protein polypeptides formulated for topical administration are tetramers.

6. The method of claim 4 wherein the recombinant multimeric protein is a heterotetrameric protein.

7. The method of claim 4 whereby administration of an effective amount of said formulation to said subject reduces UV-induced cellular damage in the subject.

8. The method of claim 1 , wherein the polypeptide sequence has no more than 2 substitutions to that of SEQ ID NO: 11 or SEQ ID NO: 12.

9. The method of claim 2 , wherein the polypeptide sequence has no more than 2 substitutions to that of SEQ ID NO: 3 or SEQ ID NO: 4.

10. The method of claim 3 , wherein the polypeptide sequence has no more than 2 substitutions to that of SEQ ID NO: 11 or SEQ ID NO: 12.

11. A method for protecting the skin from light damage in a subject in need thereof, comprising topically administering a formulation comprising a dermatologically acceptable carrier or a vehicle and a plurality of functional Brachiostoma light absorbing protein polypeptides, wherein the functional Brachiostoma light absorbing protein polypeptides independently comprise the sequence from the N-terminus:

(SEQ ID NO: 15)

Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-

Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17-

Xaa18-Xaa19-Xaa20-Xaa21-Xaa22-Xaa23-Xaa24-Xaa25-

Xaa26-Xaa27-Xaa28-Xaa29-Xaa30-Xaa31-Xaa32-Xaa33-

Xaa34-Xaa35-Xaa36-Xaa37-Xaa38-Xaa39-Xaa40-Xaa41-

Xaa42-Xaa43-Xaa44-Glu45-Xaa46-Xaa47-Xaa48-Xaa49-

Xaa50-Xaa51-Xaa52-Xaa53-Xaa54-Xaa55-Xaa56-Xaa57-

Xaa58-Xaa59-Xaa60-Trp61-Xaa62-Xaa63-Xaa64-Pro65-

Xaa66-Xaa67-G1y68-Tyr69-G1y70-Phe71-His72-Xaa73-

Xaa74-Xaa75-Xaa76-Xaa77-Xaa78-Xaa79-Xaa80-Xaa81-

Xaa82-Xaa83-Xaa84-Xaa85-Xaa86-Xaa87-Xaa88-Xaa89-

Xaa90-Xaa91-Xaa92-Xaa93-Xaa94-Xaa95-Xaa96-Xaa97-

Xaa98-Xaa99-Xaa100-Xaa101-Xaa102-Xaa103-Xaa104-

Xaa105-Xaa106-Xaa107-Xaa108-Xaa109-Xaa110-Xaa111-

Tyr112-Xaa113-Xaa114-Xaa115-Xaa116-Xaa117-Xaa118-

Xaa119-Xaa120-Xaa121-Xaa122-Xaa123-Xaa124-Xaa125-

Xaa126-Xaa127-Xaa128-Xaa129-Xaa130-Xaa131-Xaa132-

Xaa133-Xaa134-Xaa135-Xaa136-Xaa137-Xaa138-Xaa139-

Xaa140-Xaa141-Xaa142-Xaa143-Xaa144-Xaa145-Xaa146-

Xaa147-Xaa148-Xaa149-Xaa150-Xaa151-Xaa152-Xaa153-

Xaa154-Xaa155-Xaa156-Xaa157-Xaa158-Xaa159-Xaa160-

Xaa161-Xaa162-Xaa163-Xaa164-Xaa165-Xaa166-Trp167-

Xaa168-Tyr169-Xaa170-Xaa171-Xaa172-Xaa173-Xaa174-

Xaa175-Xaa176-Xaa177-Xaa178-Xaa179-Xaa180-Xaa181-

Xaa182-Xaa183-Xaa184-Xaa185-Xaa186-Xaa187-Xaa188-

Xaa189-Xaa190-Xaa191-Xaa192-Xaa193-Xaa194-Xaa195-

Xaa196-Xaa197-Xaa198-Xaa199-Xaa200-Xaa201-Xaa202-

Xaa203-Xaa204-Arg205-Xaa206-Xaa207-Xaa208-Xaa209-

Xaa210-Xaa211-Xaa212-Xaa213-Xaa214-Xaa215-Xaa216-

Xaa217-Xaa218-Xaa219-G1u220-Xaa221-Xaa222-Xaa223-

Xaa224-Xaa225,

wherein the polypeptide sequence has no more than 5 substitutions to that of SEQ ID NO: 11 or SEQ ID NO: 12; or

(SEQ ID NO: 15)

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Glu45 Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp61 Xaa Xaa

Xaa Pro65 Xaa Xaa G1y68 Tyr69 G1y70 Phe71 His72 Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Tyr112 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Trp167 Xaa Tyr169 Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Arg205 Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Glu220 Xaa Xaa

Xaa Xaa Xaa,

wherein the polypeptide sequence has no more than 5 substitutions to that of SEQ ID NO: 3 or SEQ ID NO: 4; or

(SEQ ID NO: 16)

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa G1n45 Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Trp61 Xaa Xaa

Xaa Pro65 Xaa Xaa G1y68 Tyr69 G1y70 Phe71 Tyr72 Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

His113 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Asp152 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Trp168 Xaa Tyr170 Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Arg206 Xaa Xaa Xaa Xaa Xaa

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln221 Xaa Xaa

Xaa Xaa,

wherein the polypeptide sequence no more than 5 substitutions to that of SEQ ID NO: 3 or SEQ ID NO: 4;

wherein Xaa is any amino acid.

Assignments (2)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2020

From: WANG, JIWU

To: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS, INC.

Reel/Frame 054126/0689 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2017

From: WANG, JIWU

To: ALLELE BIOTECHNOLOGY & PHARMACEUTICALS, INC.

Reel/Frame 043348/0832 →

Continuity (4)

Continuation In Part 14961678 · Dec 7, 2015

Continuation In Part 13206420 · Aug 9, 2011

Provisional Application 61371741 · Aug 9, 2010

Related Publication 20180049962A1 · Feb 22, 2018